The US FDA has approved Mylotarg seven years after Pfizer withdrew the antibody-drug conjugate due to safety concerns and questions surrounding its clinical benefit.
Seattle Genetics announced it has discontinued its Phase III Cascade trial of Vadastuximab Talirine (SGN-CD33A) for the treatment of frontline acute myeloid leukaemia (AML), due to patient deaths.
Specialist manufacturer Cellular Therapeutics has been awarded a contract from the UK Cell Therapy Catapult to produce a new cell-based cancer therapy.
Seattle Genetics has been upgraded to ‘outperform’ by an analyst based on its antibody-drug conjugate (ADC) technology platforms, pipeline and the potential of Adcetris to become a blockbuster.